NASDAQ:PYXS Pyxis Oncology (PYXS) Stock Price, News & Analysis $3.61 -0.17 (-4.50%) (As of 02:38 PM ET) Add Compare Share Share Today's Range$3.59▼$3.7950-Day Range$2.83▼$3.9452-Week Range$1.35▼$6.85Volume312,034 shsAverage Volume636,171 shsMarket Capitalization$212.59 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Pyxis Oncology alerts: Email Address Pyxis Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside149.3% Upside$9.00 Price TargetShort InterestHealthy8.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.25Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.07) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 starsMedical Sector714th out of 927 stocksPharmaceutical Preparations Industry327th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingPyxis Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePyxis Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Pyxis Oncology's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.23% of the float of Pyxis Oncology has been sold short.Short Interest Ratio / Days to CoverPyxis Oncology has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Pyxis Oncology has recently decreased by 5.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPyxis Oncology does not currently pay a dividend.Dividend GrowthPyxis Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PYXS. Previous Next 2.9 News and Social Media Coverage News SentimentPyxis Oncology has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pyxis Oncology this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pyxis Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.30% of the stock of Pyxis Oncology is held by insiders.Percentage Held by InstitutionsOnly 39.09% of the stock of Pyxis Oncology is held by institutions.Read more about Pyxis Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.07) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pyxis Oncology is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pyxis Oncology is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPyxis Oncology has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pyxis Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Pyxis Oncology Stock (NASDAQ:PYXS)Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Read More PYXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYXS Stock News HeadlinesSeptember 13 at 10:24 AM | seekingalpha.comMoment Of Truth Approaches For Pyxis OncologySeptember 7, 2024 | americanbankingnews.comAnalysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $9.00September 16, 2024 | Weiss Ratings (Ad)Protect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 29, 2024 | globenewswire.comPyxis Oncology to Participate in Two Upcoming Investor ConferencesAugust 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)August 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Gryphon Digital Mining (GRYP) and Pyxis Oncology (PYXS)August 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology Amid Strong Financials and Promising Clinical TrialsAugust 14, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024September 16, 2024 | Weiss Ratings (Ad)Protect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 8, 2024 | msn.comPyxis Oncology draws Buy at Stifel on lead assetAugust 8, 2024 | msn.comStifel Initiates Coverage of Pyxis Oncology (PYXS) with Buy RecommendationJuly 29, 2024 | globenewswire.comPyxis Oncology to Participate in the BTIG Virtual Biotechnology ConferenceJune 28, 2024 | globenewswire.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 10, 2024 | globenewswire.comPyxis Oncology Expands Board of Directors with Appointment of Michael A. MetzgerMay 30, 2024 | globenewswire.comPyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Strong Financials and Promising Clinical ProgressMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Robust Clinical Pipeline and Solid FinancialsMay 14, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024See More Headlines Receive PYXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/16/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PYXS CUSIPN/A CIK1782223 Webwww.pyxisoncology.com Phone617-221-9059FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+138.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,790,000.00 Net MarginsN/A Pretax Margin-366.67% Return on Equity-38.34% Return on Assets-30.01% Debt Debt-to-Equity RatioN/A Current Ratio9.53 Quick Ratio9.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book1.35Miscellaneous Outstanding Shares58,890,000Free Float53,411,000Market Cap$222.60 million OptionableOptionable Beta1.28 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Lara S. Sullivan M.D.MBA, CEO, President & DirectorMs. Pamela Yanchik Connealy M.B.A. (Age 62)CFO & COO Comp: $709.7kDr. Ken Kobayashi FACP (Age 63)M.D., Chief Medical Officer Comp: $314.08kMr. Jitendra Wadhane (Age 43)Chief Accounting Officer, Senior VP of Finance & Corporate Controller Dr. Balu N. Balasubramanian Ph.D.Interim Chief Technology OfficerDr. Jan Pinkas Ph.D.Chief Scientific OfficerDr. Charles T. Gombar Ph.D.Senior Vice President of Portfolio & Program ManagementMore ExecutivesKey CompetitorsMacroGenicsNASDAQ:MGNXShattuck LabsNASDAQ:STTKADC TherapeuticsNYSE:ADCTRani TherapeuticsNASDAQ:RANIAdicet BioNASDAQ:ACETView All CompetitorsInsiders & InstitutionsMillennium Management LLCBought 743,499 shares on 8/15/2024Ownership: 2.270%Blue Owl Capital Holdings LPBought 1,046,025 shares on 8/15/2024Ownership: 1.776%Susquehanna Fundamental Investments LLCSold 25,422 shares on 8/15/2024Ownership: 0.097%The Manufacturers Life Insurance Company Bought 19,730 shares on 8/15/2024Ownership: 0.034%Marshall Wace LLPSold 123,576 shares on 8/14/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions PYXS Stock Analysis - Frequently Asked Questions How have PYXS shares performed this year? Pyxis Oncology's stock was trading at $1.80 on January 1st, 2024. Since then, PYXS stock has increased by 100.6% and is now trading at $3.61. View the best growth stocks for 2024 here. How were Pyxis Oncology's earnings last quarter? Pyxis Oncology, Inc. (NASDAQ:PYXS) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. When did Pyxis Oncology IPO? Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share. Who are Pyxis Oncology's major shareholders? Top institutional investors of Pyxis Oncology include Millennium Management LLC (2.27%), Blue Owl Capital Holdings LP (1.78%), Bank of New York Mellon Corp (0.53%) and Pier 88 Investment Partners LLC (0.19%). Insiders that own company stock include Pfizer Inc, Lara Sullivan, Pamela Ann Connealy, Jitendra Wadhane, Mark Chin, Darren S Cline and Thomas Civik. View institutional ownership trends. How do I buy shares of Pyxis Oncology? Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PYXS) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
